CLASS II ONGOING Drug recall · Reported 1 Jan 2025 · FDA Enforcement Report

Duloxetine Delayed-Release Capsules, 60 mg, a) blister cards recalled

RemedyRepack is recalling Duloxetine Delayed-Release Capsules, 60 mg, a) blister cards (, distributed nationwide in the US. The recall was initiated on 2 Dec 2024 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesa) NDC 70518-0937-04, Lot # J0786744-061724, Exp. 06/30/2025 b) NDC 70518-0937-03, Lot # B3002625-060524, Exp. 10/31/2025
Quantity recalleda) 1,564 cards, b) 799 bottles

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-0165-2025
FDA event ID
95900
Recalling firm
RemedyRepack, Indiana, PA
Classification
Class II
Status
Ongoing
Recall initiated
2 Dec 2024
FDA classified
26 Dec 2024
Reported
1 Jan 2025
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Nitrosamine Impurity
Drug class
Antidepressants

Timeline

2 Dec 2024Recall initiated by company
26 Dec 2024Classified by FDA+24 days
1 Jan 2025Published in enforcement report+6 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

CGMP Deviations; presence of N-nitroso-duloxetine impurity above recommended interim limit.

Nitrosamines are impurities that can form during drug manufacturing or storage. Above the FDA acceptable intake limit, long-term exposure may raise cancer risk. The FDA advises patients to keep taking the medicine until they have a replacement.

Product as listed by the FDA

Duloxetine Delayed-Release Capsules, 60 mg, a) 30 count blister cards (NDC 70518-0937-04), b) 30 count bottles (NDC 70518-0937-03), Rx only, Source NDC 57237-0019-99, MFG: Rising Pharma, Inc., Allendale, NJ, Repackaged by: RemedyRepack Inc., Indiana, PA

Where it was distributed

Nationwide in the US

Nationwide

Questions about this recall

Why was it recalled?

CGMP Deviations; presence of N-nitroso-duloxetine impurity above recommended interim limit.

Which lots are affected?

a) NDC 70518-0937-04, Lot # J0786744-061724, Exp. 06/30/2025 b) NDC 70518-0937-03, Lot # B3002625-060524, Exp. 10/31/2025

Where was it sold?

Nationwide in the US

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 26 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from RemedyRepack

All 61

Other Duloxetine recalls

All 57